In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on IO Biotech (IOBT – Research Report). The company’s shares opened today at $0.83.
According to TipRanks, Werber is a 5-star analyst with an average return of 20.5% and a 64.12% success rate. Werber covers the Healthcare sector, focusing on stocks such as BeiGene, Generation Bio, and Nkarta.
IO Biotech has an analyst consensus of Strong Buy, with a price target consensus of $9.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $3.52 and a one-year low of $0.82. Currently, IO Biotech has an average volume of 156.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IO Biotech (IOBT) Company Description:
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Read More on IOBT:
- IO Biotech Announces 2023 Third Quarter Results
- IO Biotech completes enrollment in Phase 3 trial of advanced melanoma
- IO Biotech Announces Participation in Upcoming Investor Conferences
- IO Biotech presents three posters at SITC meeting
- IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
